{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:30:20Z","timestamp":1792135820629,"version":"4.4.0"},"reference-count":51,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mendelian diseases are caused by rare pathogenic variants with large effects. However, phenotypes are often different between individuals carrying the same variant (\u201cvariable expressivity\u201d), or even absent in some carriers (\u201cincomplete penetrance\u201d), suggesting that the genetic architecture of Mendelian diseases is more complex than previously thought. Common genetic variants are a potential modifier of observed phenotypes. Individual common variants usually have small effects, but in aggregate their effects can be substantial and be quantified as a polygenic score (PGS). The present review summarises available data on how PGS modify phenotypes in Mendelian diseases. We show that modifying effects of PGS on penetrance and expressivity have been observed in carriers of rare pathogenic variants across a broad range of conditions. This suggests that in Mendelian diseases, a modifying effect of the common variant background on penetrance and expressivity might be the rule rather than the exception. We anticipate that increasing data availability and methodological advances will improve our understanding of the genetic architecture of Mendelian diseases, including the joint consideration of both common and rare variants.<\/jats:p>","DOI":"10.1515\/medgen-2026-3014","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:57:23Z","timestamp":1783439843000},"page":"231-239","source":"Crossref","is-referenced-by-count":2,"title":["Polygenic scores as modifiers in Mendelian diseases"],"prefix":"10.1515","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9893-3850","authenticated-orcid":false,"given":"Henrike O.","family":"Heyne","sequence":"first","affiliation":[{"name":"University of Potsdam Hasso Plattner Institute for Digital Engineering, School of Medicine Prof.-Dr.-Helmert-Str. 2\u20133 Potsdam Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8541-2519","authenticated-orcid":false,"given":"Kerstin U.","family":"Ludwig","sequence":"additional","affiliation":[{"name":"University Hospital Bonn Institute of Human Genetics Venusberg Campus 1 Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9780-7243","authenticated-orcid":false,"given":"Axel","family":"Schmidt","sequence":"additional","affiliation":[{"name":"University Hospital Bonn Institute of Human Genetics Venusberg Campus 1 Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026072106573424500_j_medgen-2026-3014_ref_001","doi-asserted-by":"crossref","unstructured":"Pilling LC, Atkins JL, Melzer D. Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: Associations in a large community cohort. Hepatology. Baltimore, Md.; 2022;76:1735\u201345. https:\/\/doi.org\/10.1002\/hep.32575","DOI":"10.1002\/hep.32575"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_002","doi-asserted-by":"crossref","unstructured":"Fahed AC, Wang M, Homburger JR, Patel AP, Bick AG, Neben CL, et al. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. Nat Commun. 2020;11:3635. https:\/\/doi.org\/10.1038\/s41467-020-17374-3","DOI":"10.1038\/s41467-020-17374-3"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_003","doi-asserted-by":"crossref","unstructured":"Oliver KL, Scheffer IE, Ellis CA, Grinton BE, Epi4K Consortium, Berkovic SF, et al. Investigating the effect of polygenic background on epilepsy phenotype in \u201cmonogenic\u201d families. EBioMedicine. 2024;109:105404. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105404","DOI":"10.1016\/j.ebiom.2024.105404"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_004","unstructured":"McDonald-McGinn DM, Hain HS, Emanuel BS, Zackai EH. 22q11.2 Deletion Syndrome. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2026 Mar 11]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1523\/. Accessed 11 Mar 2026"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_005","doi-asserted-by":"crossref","unstructured":"Kingdom R, Wright CF. Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts. Front Genet. 2022;13:920390. https:\/\/doi.org\/10.3389\/fgene.2022.920390","DOI":"10.3389\/fgene.2022.920390"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_006","doi-asserted-by":"crossref","unstructured":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium. Identification of Genetic Factors that Modify Clinical Onset of Huntington\u2019s Disease. Cell. 2015;162:516\u201326. https:\/\/doi.org\/10.1016\/j.cell.2015.07.003","DOI":"10.1016\/j.cell.2015.07.003"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_007","doi-asserted-by":"crossref","unstructured":"Claussnitzer M, Cho JH, Collins R, Cox NJ, Dermitzakis ET, Hurles ME, et al. A brief history of human disease genetics. Nature. 2020;577:179\u201389. https:\/\/doi.org\/10.1038\/s41586-019-1879-7","DOI":"10.1038\/s41586-019-1879-7"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_008","doi-asserted-by":"crossref","unstructured":"Choi SW, Mak TS-H, O\u2019Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15:2759\u201372. https:\/\/doi.org\/10.1038\/s41596-020-0353-1","DOI":"10.1038\/s41596-020-0353-1"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_009","doi-asserted-by":"crossref","unstructured":"Falconer DS. The inheritance of liability to certain diseases, estimated from the incidence among relatives. Ann Hum Genet. 1965;29:51\u201376. https:\/\/doi.org\/10.1111\/j.1469-1809.1965.tb00500.x","DOI":"10.1111\/j.1469-1809.1965.tb00500.x"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_010","doi-asserted-by":"crossref","unstructured":"Carter CO, Evans KA. Inheritance of congenital pyloric stenosis. J Med Genet. 1969;6:233\u201354. https:\/\/doi.org\/10.1136\/jmg.6.3.233","DOI":"10.1136\/jmg.6.3.233"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_011","doi-asserted-by":"crossref","unstructured":"Baya NA, Lassen FH, Hill B, Venkatesh SS, Currant H, Lindgren CM, et al. Individuals whose phenotype deviates from genetic expectation defined by common variation are enriched for rare damaging variants in genes that cause rare disease [Internet]. 2025 [cited 2026 Mar 11]. https:\/\/doi.org\/10.64898\/2025.12.30.25343229","DOI":"10.64898\/2025.12.30.25343229"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_012","doi-asserted-by":"crossref","unstructured":"Huang QQ, Wigdor EM, Malawsky DS, Campbell P, Samocha KE, Chundru VK, et al. Examining the role of common variants in rare neurodevelopmental conditions. Nature. 2024;636:404\u201311. https:\/\/doi.org\/10.1038\/s41586-024-08217-y","DOI":"10.1038\/s41586-024-08217-y"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_013","doi-asserted-by":"crossref","unstructured":"Jansen S, Vissers LELM, de Vries BBA. The Genetics of Intellectual Disability. Brain Sci. 2023;13:231. https:\/\/doi.org\/10.3390\/brainsci13020231","DOI":"10.3390\/brainsci13020231"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_014","doi-asserted-by":"crossref","unstructured":"Chen Y, Dawes R, Kim HC, Ljungdahl A, Stenton SL, Walker S, et al. De novo variants in the RNU4-2 snRNA cause a frequent neurodevelopmental syndrome. Nature. 2024;632:832\u201340. https:\/\/doi.org\/10.1038\/s41586-024-07773-7","DOI":"10.1038\/s41586-024-07773-7"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_015","doi-asserted-by":"crossref","unstructured":"Niemi MEK, Martin HC, Rice DL, Gallone G, Gordon S, Kelemen M, et al. Common genetic variants contribute to risk of rare severe neurodevelopmental disorders. Nature. 2018;562:268\u201371. https:\/\/doi.org\/10.1038\/s41586-018-0566-4","DOI":"10.1038\/s41586-018-0566-4"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_016","doi-asserted-by":"crossref","unstructured":"Kingdom R, Beaumont RN, Wood AR, Weedon MN, Wright CF. Genetic modifiers of rare variants in monogenic developmental disorder loci. Nat Genet. 2024;56:861\u20138. https:\/\/doi.org\/10.1038\/s41588-024-01710-0","DOI":"10.1038\/s41588-024-01710-0"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_017","doi-asserted-by":"crossref","unstructured":"Klei L, McClain LL, Mahjani B, Panayidou K, De Rubeis S, Grahnat A-CS, et al. How rare and common risk variation jointly affect liability for autism spectrum disorder. Mol Autism. 2021;12:66. https:\/\/doi.org\/10.1186\/s13229-021-00466-2","DOI":"10.1186\/s13229-021-00466-2"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_018","doi-asserted-by":"crossref","unstructured":"Weiner DJ, Wigdor EM, Ripke S, Walters RK, Kosmicki JA, Grove J, et al. Polygenic transmission disequilibrium confirms that common and rare variation act additively to create risk for autism spectrum disorders. Nat Genet. 2017;49:978\u201385. https:\/\/doi.org\/10.1038\/ng.3863","DOI":"10.1038\/ng.3863"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_019","doi-asserted-by":"crossref","unstructured":"Davies RW, Fiksinski AM, Breetvelt EJ, Williams NM, Hooper SR, Monfeuga T, et al. Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome. Nat Med. 2020;26:1912\u20138. https:\/\/doi.org\/10.1038\/s41591-020-1103-1","DOI":"10.1038\/s41591-020-1103-1"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_020","doi-asserted-by":"crossref","unstructured":"Piet MM, Braun KPJ, Koeleman BPC, Stevelink R. Monogenic no more: are all epilepsies polygenic? Trends Genet TIG. 2026;S0168-9525(26)00005-3. https:\/\/doi.org\/10.1016\/j.tig.2026.01.005","DOI":"10.1016\/j.tig.2026.01.005"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_021","doi-asserted-by":"crossref","unstructured":"Stevelink R, Piet MM, Bos Y, van \u2019t Slot R, Braun KPJ, Koeleman BPC. Penetrance of pathogenic epilepsy variants is low and shaped by common genetic background. Epilepsia. 2025; https:\/\/doi.org\/10.1111\/epi.70018","DOI":"10.1101\/2025.10.16.25338116"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_022","doi-asserted-by":"crossref","unstructured":"Campbell C, Leu C, Feng Y-CA, Wolking S, Moreau C, Ellis C, et al. The role of common genetic variation in presumed monogenic epilepsies. EBioMedicine. 2022;81:104098. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104098","DOI":"10.1016\/j.ebiom.2022.104098"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_023","doi-asserted-by":"crossref","unstructured":"Iwaki H, Blauwendraat C, Makarious MB, Bandr\u00e9s-Ciga S, Leonard HL, Gibbs JR, et al. Penetrance of Parkinson\u2019s Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Mov Disord Off J Mov Disord Soc. 2020;35:774\u201380. https:\/\/doi.org\/10.1002\/mds.27974","DOI":"10.1002\/mds.27974"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_024","doi-asserted-by":"crossref","unstructured":"Cho BPH, Harshfield EL, Al-Thani M, Tozer DJ, Bell S, Markus HS. Association of Vascular Risk Factors and Genetic Factors With Penetrance of Variants Causing Monogenic Stroke. JAMA Neurol. 2022;79:1303\u201311. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3832","DOI":"10.1001\/jamaneurol.2022.3832"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_025","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2026 May 29]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1247\/. Accessed 29 May 2026"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_026","doi-asserted-by":"crossref","unstructured":"Kuchenbaecker KB, McGuffog L, Barrowdale D, Lee A, Soucy P, Dennis J, et al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017;109:djw302. https:\/\/doi.org\/10.1093\/jnci\/djw302","DOI":"10.1093\/jnci\/djw302"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_027","doi-asserted-by":"crossref","unstructured":"Hassanin E, May P, Aldisi R, Spier I, Forstner AJ, N\u00f6then MM, et al. Breast and prostate cancer risk: The interplay of polygenic risk, rare pathogenic germline variants, and family history. Genet Med Off J Am Coll Med Genet. 2022;24:576\u201385. https:\/\/doi.org\/10.1016\/j.gim.2021.11.009","DOI":"10.1016\/j.gim.2021.11.009"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_028","doi-asserted-by":"crossref","unstructured":"Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, et al. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:2240\u201350. https:\/\/doi.org\/10.1200\/JCO.2016.69.4935","DOI":"10.1200\/JCO.2016.69.4935"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_029","doi-asserted-by":"crossref","unstructured":"Kurki MI, Karjalainen J, Palta P, Sipil\u00e4 TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613:508\u201318. https:\/\/doi.org\/10.1038\/s41586-022-05473-8","DOI":"10.1038\/s41586-022-05473-8"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_030","doi-asserted-by":"crossref","unstructured":"Mars N, Wid\u00e9n E, Kerminen S, Meretoja T, Pirinen M, Della Briotta Parolo P, et al. The role of polygenic risk and susceptibility genes in breast cancer over the course of life. Nat Commun. 2020;11:6383. https:\/\/doi.org\/10.1038\/s41467-020-19966-5","DOI":"10.1101\/2020.04.17.20069229"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_031","doi-asserted-by":"crossref","unstructured":"Kvist A, K\u00e4mpe A, T\u00f6rngren T, Tesi B, Baliakas P, Borg \u00c5, et al. Polygenic scores in Familial breast cancer cases with and without pathogenic variants and the risk of contralateral breast cancer. Breast Cancer Res BCR. 2025;27:160. https:\/\/doi.org\/10.1186\/s13058-025-02107-5","DOI":"10.1186\/s13058-025-02107-5"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_032","doi-asserted-by":"crossref","unstructured":"Hassanin E, Spier I, Bobbili DR, Aldisi R, Klinkhammer H, David F, et al. Clinically relevant combined effect of polygenic background, rare pathogenic germline variants, and family history on colorectal cancer incidence. BMC Med Genomics. 2023;16:42. https:\/\/doi.org\/10.1186\/s12920-023-01469-z","DOI":"10.1186\/s12920-023-01469-z"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_033","doi-asserted-by":"crossref","unstructured":"Jenkins MA, Buchanan DD, Lai J, Makalic E, Dite GS, Win AK, et al. Assessment of a Polygenic Risk Score for Colorectal Cancer to Predict Risk of Lynch Syndrome Colorectal Cancer. JNCI Cancer Spectr. 2021;5:pkab022. https:\/\/doi.org\/10.1093\/jncics\/pkab022","DOI":"10.1093\/jncics\/pkab022"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_034","doi-asserted-by":"crossref","unstructured":"Due\u00f1as N, Klinkhammer H, Bonifaci N, Spier I, Mayr A, Hassanin E, et al. Ability of a polygenic risk score to refine colorectal cancer risk in Lynch syndrome. J Med Genet. 2023;60:1044\u201351. https:\/\/doi.org\/10.1136\/jmg-2023-109344","DOI":"10.1136\/jmg-2023-109344"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_035","doi-asserted-by":"crossref","unstructured":"Paquette M, Chong M, Th\u00e9riault S, Dufour R, Par\u00e9 G, Baass A. Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia. J Clin Lipidol. 2017;11:725\u2013732.e5. https:\/\/doi.org\/10.1016\/j.jacl.2017.03.019","DOI":"10.1016\/j.jacl.2017.03.019"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_036","doi-asserted-by":"crossref","unstructured":"Futema M, Bourbon M, Williams M, Humphries SE. Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia. Atherosclerosis. 2018;277:457\u201363. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.006","DOI":"10.1016\/j.atherosclerosis.2018.06.006"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_037","doi-asserted-by":"crossref","unstructured":"Murray Leech J, Beaumont RN, Arni AM, Chundru VK, Sharp LN, Colclough K, et al. Common genetic variants modify disease risk and clinical presentation in monogenic diabetes. Nat Metab. 2025;7:1819\u201329. https:\/\/doi.org\/10.1038\/s42255-025-01372-0","DOI":"10.1038\/s42255-025-01372-0"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_038","doi-asserted-by":"crossref","unstructured":"Aksit MA, Pace RG, Vecchio-Pag\u00e1n B, Ling H, Rommens JM, Boelle P-Y, et al. Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits. J Clin Endocrinol Metab. 2020;105:1401\u201315. https:\/\/doi.org\/10.1210\/clinem\/dgz102","DOI":"10.1210\/clinem\/dgz102"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_039","doi-asserted-by":"crossref","unstructured":"Klasfeld SJ, Knutson KA, Miller MR, Fauman EB, Berghout J, Moccia R, et al. Common genetic modifiers influence cardiomyopathy susceptibility among the carriers of rare pathogenic variants. HGG Adv. 2025;6:100460. https:\/\/doi.org\/10.1016\/j.xhgg.2025.100460","DOI":"10.1016\/j.xhgg.2025.100460"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_040","doi-asserted-by":"crossref","unstructured":"Wijdeveld LFJM, Ajufo E, Challa SP, R\u00e4m\u00f6 JT, Wang X, Kany S, et al. Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation. JAMA Cardiol. 2025;10:564\u201373. https:\/\/doi.org\/10.1001\/jamacardio.2025.0460","DOI":"10.1001\/jamacardio.2025.0460"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_041","doi-asserted-by":"crossref","unstructured":"Wanner JS, Krafft M, Niiranen T, Zimmerman DS, FinnGen null, Ellinor PT, et al. Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade. Circulation. 2025;152:1679\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.075057","DOI":"10.1161\/CIRCULATIONAHA.125.075057"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_042","doi-asserted-by":"crossref","unstructured":"Khan A, Shang N, Nestor JG, Weng C, Hripcsak G, Harris PC, et al. Polygenic risk alters the penetrance of monogenic kidney disease. Nat Commun. 2023;14:8318. https:\/\/doi.org\/10.1038\/s41467-023-43878-9","DOI":"10.1038\/s41467-023-43878-9"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_043","doi-asserted-by":"crossref","unstructured":"Craig JE, Han X, Qassim A, Hassall M, Cooke Bailey JN, Kinzy TG, et al. Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. Nat Genet. 2020;52:160\u20136. https:\/\/doi.org\/10.1038\/s41588-019-0556-y","DOI":"10.1038\/s41588-019-0556-y"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_044","doi-asserted-by":"crossref","unstructured":"Zebardast N, Sekimitsu S, Wang J, Elze T, Gharahkhani P, Cole BS, et al. Characteristics of p.Gln368Ter Myocilin Variant and Influence of Polygenic Risk on Glaucoma Penetrance in the UK Biobank. Ophthalmology. 2021;128:1300\u201311. https:\/\/doi.org\/10.1016\/j.ophtha.2021.03.007","DOI":"10.1016\/j.ophtha.2021.03.007"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_045","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Minguet D, Noel R, G Sim\u00f3n A, Pastor \u00d3. Challenges in clinical translation of polygenic risk score analyses: A systematic review. Genet Med Off J Am Coll Med Genet. 2026;28:101662. https:\/\/doi.org\/10.1016\/j.gim.2025.101662","DOI":"10.1016\/j.gim.2025.101662"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_046","doi-asserted-by":"crossref","unstructured":"Ellis CA, Oliver KL, Harris RV, Ottman R, Scheffer IE, Mefford HC, et al. Inflation of polygenic risk scores caused by sample overlap and relatedness: Examples of a major risk of bias. Am J Hum Genet. 2024;111:1805\u20139. https:\/\/doi.org\/10.1016\/j.ajhg.2024.07.014","DOI":"10.1016\/j.ajhg.2024.07.014"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_047","doi-asserted-by":"crossref","unstructured":"Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51:584\u201391. https:\/\/doi.org\/10.1038\/s41588-019-0379-x","DOI":"10.1038\/s41588-019-0379-x"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_048","doi-asserted-by":"crossref","unstructured":"Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med Off J Am Coll Med Genet. 2019;21:1708\u201318. https:\/\/doi.org\/10.1038\/s41436-018-0406-9","DOI":"10.1038\/s41436-018-0406-9"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_049","doi-asserted-by":"crossref","unstructured":"Yang X, Mooij TM, Leslie G, Ficorella L, Andrieu N, Kast K, et al. Validation of the BOADICEA model in a prospective cohort of BRCA1\/2 pathogenic variant carriers. J Med Genet. 2024;61:803\u20139. https:\/\/doi.org\/10.1136\/jmg-2024-109943","DOI":"10.1136\/jmg-2024-109943"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_050","doi-asserted-by":"crossref","unstructured":"100,000 Genomes Project Pilot Investigators, Smedley D, Smith KR, Martin A, Thomas EA, McDonagh EM, et al. 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care \u2013 Preliminary Report. N Engl J Med. 2021;385:1868\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2035790","DOI":"10.1056\/NEJMoa2035790"},{"key":"2026072106573424500_j_medgen-2026-3014_ref_051","doi-asserted-by":"crossref","unstructured":"Breen G. Common genetic variants contribute more to rare diseases than previously thought. Nature. 2024;636:304\u20135. https:\/\/doi.org\/10.1038\/d41586-024-03554-4","DOI":"10.1038\/d41586-024-03554-4"}],"container-title":["Medizinische Genetik"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2026-3014\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2026-3014\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:58:22Z","timestamp":1784617102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2026-3014\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,7,7]]}},"alternative-id":["10.1515\/medgen-2026-3014"],"URL":"https:\/\/doi.org\/10.1515\/medgen-2026-3014","relation":{},"ISSN":["1863-5490","0936-5931"],"issn-type":[{"value":"1863-5490","type":"electronic"},{"value":"0936-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}